Intrexon appoints Andrew J. Last as COO
Dr. Last brings to Intrexon 30 years of experience spanning life sciences, including biotechnology, genomics, clinical diagnostics, pharmaceuticals and agrochemicals, with several industry leading companies.
Most recently Dr. Last served as the Executive Vice President and Chief Operating Officer of Affymetrix where he was responsible for directing five business units, and overseeing strategic marketing, product management, R&D, clinical operations, regulatory affairs, QA/QC, and overall manufacturing operations for the company.
Additionally, he was a member of the Affymetrix management team. Dr. Last also previously served as the Chief Commercial Officer of Affymetrix directly managing global sales, product management, field marketing, service and support.
Prior to joining Affymetrix, Dr. Last was Vice President, Global & Strategic Marketing of Becton Dickinson' BioSciences Cell Analysis Division & General Manager of Pharmingen, contributing as a member of the executive management team responsible for overall business strategy and execution, as well as driving development across a broad product portfolio.
He has also held executive positions with Applied Biosystems and Incyte Genomics.
Further, Dr. Last spent a significant tenure with Monsanto Company serving in numerous leadership positions including Director, Worldwide Business and Category Management, and Director, Ortho Home & Garden, for the Solaris Group, as well as Manager, Innovation and Product Development, Europe/Africa, for the Agricultural Group. He is currently an independent member of the Board of Directors of Oncocyte Corporation.
Dr. Last received a Bachelor's Degree in Biological Sciences from the University of Leicester, UK and a Master's degree in Bio-Aeronautics, as well as a Ph.D. in Agrochemical Specialization, from Cranfield University in the UK. ■
LATEST MOVES FROM Maryland
- Eagle Bancorp appoints Susan G. Riel to board
- Colfax Corporation appoints Didier Teirlinck to board
- Lockheed Martin appoints Stephanie C. Hill as vice president
- Global Medical REIT president Jeffrey Busch to take CEO role
- U.S. Silica adds Diane K. Duren to board
More inside POST